Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
169.7 USD | +0.69% | +5.18% | +9.43% |
12:00pm | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Jun. 06 | AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint | MT |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Transcripts